Mercury in Vaccines Exceed EPA’s Maximum

by | Oct 15, 2009


A green chalkboard with the message 'I LOVE YOU' written in white chalk.Most of the 120 million doses of the 2009-2010 Seasonal Flu Vaccine, as well as most of the 250 million doses of the 2009 pandemic H1N1 Swine flu vaccine contain toxic levels of Mercury.


Mercury is used as a preservative in vaccines, known as Thimerosal, eventhough the Public Health Service (PHS) agencies, including the FDA, the CDC, the American Academy of Pediatrics (AAP) and vaccine manufacturers agreed in July 1999 that Thimerosal should be reduced or eliminated from all vaccines as soon as possible.


Most injected flu vaccine currently available contains 25 micrograms (mcg) of mercury in the form of Thimerosal (ethylmercury thiosalicylate). Children first receive one-half of the adult dose, or 12.5 micrograms of mercury, followed within a four week period by a second dose of 12.5 micrograms of mercury, for a total of 25 micrograms.


According to the EPA, the maximum acceptable daily risk level is 0.1 mcg/kg. The current vaccine will inject the average child with 12-17 times the maximum daily amount of mercury recommended by the EPA and the average adult with 3.5 times the maximum amount. However, most concerning is the fact that the vaccines will expose the unborn fetus of a pregnant women to 250 times the maximum recommended dose of mercury.


The EPA guidelines are only recommendations for consumption of methyl-mercury typically consumed in fish. There are no guidelines for the more dangerous practice of “injecting” the more toxic ethyl-mercury directly into the human bloodstream.


Mercury is a known neurotoxin that crosses the blood-brain barrier and is especially dangerous to infants and a developing fetus. Mercury has been causally linked to the dramatically increasing incidence of autism and other neurological diseases. Cases of autism in the U.S. have increased by 1,500 per cent since 1991, which is when vaccines for children doubled, and the number of immunizations is only increasing. Just one in 2,500 children were diagnosed with autism before 1991, whereas one in 150 children now have the disease.


Even Trace Amounts of Mercury in the so called “Thimerosal-Free” Vaccines are Toxic

Some Vaccine Manufacturers claim that they provide “Thimerosal-Free” vaccine in single dose syringes. However, the truth is that even the “Thimerosal-Free” doses contain toxic amounts of Mercury. Thimerosal is used in the early stages of vaccine manufacture and is subsequently removed by purification steps to what is called “a trace amount.” The “trace amount” equals 1 microgram of Mercury or less per 0.5 mL dose.


1 microgram (mcg) of Mercury per 0.5mL vaccine dose is equivalent to 2000 mcg per liter, which equals 2000 parts per billion (2000 ppb).

2 ppb mercury is the U.S. EPA limit for drinking water (http://www.epa.gov/safewater/contaminants /index.html#mcls).

20 ppb mercury destroys neurite membranes (nerve tissue in the brain) (Leong et al., Neuroreport 2001; 12:733-7). An amount thought to be sufficient to cause Autism.

200 ppb mercury is the level in liquid that the EPA classifies as hazardous waste (http://www.epa.gov/ epaoswer/hazwaste/mercury/ regs.htm#hazwaste).

25,000 ppb mercury is equivalent to 25 mcg, which is the concentration of mercury in each dose dispensed from the multi-dose vials of both the seasonal influenza vaccine as well as the pandemic H1N1 flu vaccine in the U.S.


References:

http://www.epa.gov/safewater/contaminants /index.html#mcls

http://jcn.sagepub.com/cgi/content/abstract/22/11/1308

http://www.cdc.gov/vaccinesafety/updates/thimerosal_faqs_thimerosal.htm

http://www.cdc.gov/h1n1flu/vaccination/thimerosal_qa.htm

Mercury in Vaccines Linked to Autism: Medical Research

Vacciness/Mercury/Autism: CDC’s Conflict of Interest

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

4 + 10 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });